{"id":"escitalopram-celecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Cardiovascular risk (celecoxib)"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:18:06.091707","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Escitalopram increases serotonin availability in the central nervous system by blocking its reuptake, treating depression and anxiety. Celecoxib selectively inhibits COX-2, reducing prostaglandin production and inflammation while sparing COX-1, thereby reducing pain and inflammation with potentially lower gastrointestinal toxicity than non-selective NSAIDs.","oneSentence":"This combination pairs a selective serotonin reuptake inhibitor with a selective cyclooxygenase-2 inhibitor to address both mood and inflammatory symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:45:45.861Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Depression with concurrent pain or inflammatory conditions"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT01479829","phase":"PHASE4","title":"Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression","status":"COMPLETED","sponsor":"Loyola University","startDate":"2011-03-23","conditions":"Bipolar Depression","enrollment":100},{"nctId":"NCT02389465","phase":"PHASE4","title":"Stress and Inflammation in Late-Life Depression","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-08","conditions":"Depression, Inflammation","enrollment":119},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2017","pmid":"29270399","title":"Diminution of Heart Rate Variability in Bipolar Depression.","journal":"Frontiers in public health"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Escitalopram + Celecoxib","genericName":"Escitalopram + Celecoxib","companyName":"University of Pennsylvania","companyId":"university-of-pennsylvania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination pairs a selective serotonin reuptake inhibitor with a selective cyclooxygenase-2 inhibitor to address both mood and inflammatory symptoms. Used for Depression with concurrent pain or inflammatory conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}